Roze S - Search Results

1

An economic evaluation of the Irbesartan in Diabetic Nephropathy Trial (IDNT) in a UK setting.

Palmer AJ, Annemans L, Roze S, Lamotte M, Rodby RA, Bilous RW. Palmer AJ, et al. Among authors: roze s. J Hum Hypertens. 2004 Oct;18(10):733-8. doi: 10.1038/sj.jhh.1001729. J Hum Hypertens. 2004. PMID: 15116142 Clinical Trial.

2

[Health economic consequences of the use of irbesartan in patients in Germany with type 2 diabetes, nephropathy and hypertension].

Palmer AJ, Annemans L, Roze S, Lamotte M, Rodby RA, Ritz E. Palmer AJ, et al. Among authors: roze s. Dtsch Med Wochenschr. 2004 Jan 2;129(1-2):13-8. doi: 10.1055/s-2004-812656. Dtsch Med Wochenschr. 2004. PMID: 14703575 German.

3

Cost-consequence analysis in a French setting of screening and optimal treatment of nephropathy in hypertensive patients with type 2 diabetes.

Palmer AJ, Chen R, Valentine WJ, Roze S, Bregman B, Mehin N, Gabriel S. Palmer AJ, et al. Among authors: roze s. Diabetes Metab. 2006 Feb;32(1):69-76. doi: 10.1016/s1262-3636(07)70249-5. Diabetes Metab. 2006. PMID: 16523189

4

[Clinical and health economic implications of early treatment with irbesartan of patients with type 2 diabetes mellitus, hypertension and nephropathy].

Palmer AJ, Roze S, Rodby RA, Valentine WJ, Ritz E, Lehnert H. Palmer AJ, et al. Among authors: roze s. Dtsch Med Wochenschr. 2006 Aug 4;131(31-32):1721-6. doi: 10.1055/s-2006-947822. Dtsch Med Wochenschr. 2006. PMID: 16868875 German.

5

The cost-effectiveness of irbesartan in the treatment of hypertensive patients with type 2 diabetic nephropathy.

Rodby RA, Chiou CF, Borenstein J, Smitten A, Sengupta N, Palmer AJ, Roze S, Annemans L, Simon TA, Chen RS, Lewis EJ; Collaborative Study Group. Rodby RA, et al. Among authors: roze s. Clin Ther. 2003 Jul;25(7):2102-19. doi: 10.1016/s0149-2918(03)80208-4. Clin Ther. 2003. PMID: 12946554

6

An economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy: cost-effectiveness of Irbesartan in Diabetic Nephropathy Trial (IDNT) in the Belgian and French settings.

Palmer AJ, Annemans L, Roze S, Lamotte M, Rodby RA, Cordonnier DJ. Palmer AJ, et al. Among authors: roze s. Nephrol Dial Transplant. 2003 Oct;18(10):2059-66. doi: 10.1093/ndt/gfg232. Nephrol Dial Transplant. 2003. PMID: 13679481

7

Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and renal disease.

Palmer AJ, Annemans L, Roze S, Lamotte M, Lapuerta P, Chen R, Gabriel S, Carita P, Rodby RA, de Zeeuw D, Parving HH. Palmer AJ, et al. Among authors: roze s. Diabetes Care. 2004 Aug;27(8):1897-903. doi: 10.2337/diacare.27.8.1897. Diabetes Care. 2004. PMID: 15277414

8

Irbesartan is projected to be cost and life saving in a Spanish setting for treatment of patients with type 2 diabetes, hypertension, and microalbuminuria.

Palmer AJ, Annemans L, Roze S, Lapuerta P, Chen R, Gabriel S, Carita P, Rodby RA, de Zeeuw D, Parving HH, De Alvaro F. Palmer AJ, et al. Among authors: roze s. Kidney Int Suppl. 2005 Jan;(93):S52-4. doi: 10.1111/j.1523-1755.2005.09312.x. Kidney Int Suppl. 2005. PMID: 15613069 Free article.

9

Cost-effectiveness of irbesartan in diabetic nephropathy: a systematic review of published studies.

Palmer AJ, Tucker DM, Valentine WJ, Roze S, Gabriel S, Cordonnier DJ. Palmer AJ, et al. Among authors: roze s. Nephrol Dial Transplant. 2005 Jun;20(6):1103-9. doi: 10.1093/ndt/gfh802. Epub 2005 Apr 26. Nephrol Dial Transplant. 2005. PMID: 15855214 Review.

10

A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension.

Palmer AJ, Valentine WJ, Tucker DM, Ray JA, Roze S, Annemans L, Lapuerta P, Chen R, Gabriel S, Carita P, Rodby RA, de Zeeuw D, Parving HH, Laville M. Palmer AJ, et al. Among authors: roze s. Curr Med Res Opin. 2006 Nov;22(11):2095-100. doi: 10.1185/030079906X132730. Curr Med Res Opin. 2006. PMID: 17076969

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

113 results

Search Page

Filters